However, according to existing expert consensus in the field, high-dose methotrexate-based chemotherapy combined with multiple treatments is commonly used to curb the development of PCNSL.[18] Combined with methotrexate, rituximab, which is a traditional chemotherapeutic agent and specifically targets CD20, has been widely used in systemic lymphoma. This evidence concerns the gene MS4A1 and primary central nervous system lymphoma.